Patents by Inventor Gyorgi Keri

Gyorgi Keri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of platelet derived growth factor related disorders such as cancers
    Patent number: 5990141
    Abstract: The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.
    Type: Grant
    Filed: January 6, 1995
    Date of Patent: November 23, 1999
    Assignee: Sugen Inc.
    Inventors: Klaus Peter Hirth, Donna Pruess Schwartz, Elaina Mann, Laura Kay Shawver, Gyorgi Keri, Istvan Szekely, Tamas Bajor, Janis Haimichael, Laszlo Orfi, Alex Levitzki, Aviv Gazit, Axel Ullrich, Reiner Lammers, Fairooz F. Kabbinavar, Dennis Slamon, Peng Cho Tang
  • Treatment of platelet derived growth factor related disorders such as cancers
    Patent number: 5932602
    Abstract: The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: August 3, 1999
    Assignees: Sugen, Inc., Biosignal Ltd., The Regents of the University of California, Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V., Yissum Research and Development Company of the Hebrew University of Jerusalem
    Inventors: Klaus Peter Hirth, Laura Kay Shawver, Gyorgi Keri, Istvan Szekely, Janis Haimichael, Axel Ullrich, Reiner Lammers
  • Treatment of platelet derived growth factor related disorders such as cancers
    Patent number: 5700822
    Abstract: The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: December 23, 1997
    Assignee: The Regents of the University of California
    Inventors: Klaus Peter Hirth, Donna Pruess Schwartz, Elaina Mann, Laura Kay Shawver, Gyorgi Keri, Istvan Szekely, Tamas Bajor, Janis Haimichael, Laszlo Orfi, Alex Levitzki, Aviv Gazit, Axel Ullrich, Reiner Lammers, Fairooz F. Kabbinavar, Dennis Slamon, Peng Cho Tang
  • Gonadoliberin derivatives process for the preparation and pharmaceutical compositions thereof
    Patent number: 4552864
    Abstract: The invention relates to new gonadoliberin derivatives of the formula (I)Glp-His-Trp-Ser-Tyr-X-Leu-Arg-Pro-Y, (I)whereinY represents a glycine-amide group or an -NH-alkyl group having 1 to 4 carbon atoms in the alkyl moiety,X stands for a D-thyroxyl, D-thyronyl or D-4-chlorophenylalanyl group,and acid addition salts and metal complexes thereof.The new nona- and decapeptide derivatives have an excellent luteinizing and folliculus stimulating hormone releasing activity, and they can therefore be used as active ingredients in pharmaceutical compositions for human or veterinary application.
    Type: Grant
    Filed: May 4, 1984
    Date of Patent: November 12, 1985
    Assignee: Reanal Finomvegyszergyar
    Inventors: Ferenc Antoni, Judit Erchegyi, Aniko Horvath, Gyorgi Keri, Imre Mezo, Karoly Nikolics, Janos Seprodi, Andras Szell, Balazs Szoke, Istvan Teplan